DNL952
Phase 1Small molecule
DNL952 is one of 28 small molecule programs targeting Pompe Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
38 competitors in Pompe Disease
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Trexall
Alnylam PharmaceuticalsApproved
Asceniv
CSL BehringApproved
Velcade
SShilpa Grover, MD, MPH
Approved
Salbutamol
GSKApproved
Opfolda
Johnson & JohnsonPhase 3
BMN 333
BioMarin PharmaceuticalPhase 3
Clenbuterol
UUniversity of Copenhagen
Phase 2
Proair HFA
GGlaxo Dba Glaxosmithkline
Phase 1
Tylenol
KKenvue Brands
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DNL952. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- DDenali Therapeutics Inc.